A. Birner

发表

Pharmacology of oral chemotherapy agents.

A. Birner, 2003, Clinical journal of oncology nursing.

Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

D. Esseltine, S. Treon, I. Ghobrial, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral chemotherapy.

A. Birner, Megan Rezendes, 2005, Clinical Journal of Oncology Nursing.

Photosensitivity Associated with Fluorouracil, Prochlorperazine, and Topical Tretinoin

L. Meyer, A. Birner, 2001, Pharmacotherapy.

A complex case of ibrutinib treatment for a CLL patient on haemodialysis

M. Davids, A. Aw, A. Birner, 2018, British journal of haematology.

Safe administration of oral chemotherapy.

A. Birner, 2003, Clinical journal of oncology nursing.

Program to support safe administration of oral chemotherapy.

M. Ernstoff, J. Avery, A. Birner, 2006, Journal of oncology practice.

Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial.

S. Jagannath, N. Munshi, P. Richardson, 2006 .

Characterization of hemopoietic cell populations from human cord blood expressing c-kit.

A. Ullrich, B. Kempkes, R. Mailhammer, 1993, Experimental hematology.

Activity of the NEDD8-specific inhibitor MLN 4924 in multiple myeloma and Waldenström's macroglobulinemia, and effect on miRNA expression.

K. Anderson, D. McMillin, Jake E. Delmore, 2010 .

Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma

R. Vij, N. Munshi, J. Laubach, 2008 .

Recombinant murine interleukin 9 enhances the erythropoietin-dependent colony formation of human BFU-E.

L. Hültner, J. Van Snick, P. Dörmer, 1992, Experimental hematology.